CENTOGENE Receives Delisting Notice From Nasdaq, Effective At The Open Of Trading On August 8, 2024
CENTOGENE Receives Delisting Notice From Nasdaq, Effective At The Open Of Trading On August 8, 2024
Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE'S common stock from Nasdaq. The notice indicates that CENTOGENE (the "Company") remains noncompliant with Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum USD 15 million market value of publicly held shares.
Centogene N.V.是罕見疾病和神經退行性疾病數據驅動答案的基本生命科學合作伙伴，今天宣佈收到納斯達克證券市場有限責任公司（“納斯達克”）的通知，指示納斯達克聽證會委員會已決定從納斯達克除牌CENTOGENE的普通股。通知顯示CENTOGENE代表的公司仍然未達到納斯達克上市規則5450(b)(2)(C)的要求，該要求需要公開持有股份的最低美元指數1500萬市值。
Suspension of trading in the Company's common stock on Nasdaq will be effective at the open of trading on August 8, 2024. The Company may, within 15 calendar days from the date of the notice, request that Nasdaq review the decision, but the Company does not intend to make such a request.
公司的普通股在納斯達克的交易暫停將於2024年8月8日開盤時生效。公司可以在通知日期後15個日曆日內要求納斯達克審查決定，但公司不打算這樣做。
譯文內容由第三人軟體翻譯。